Interpace Diagnostics Group Inc. (NASDAQ:IDXG) on April 18 skyrocketed by 75.81% in intraday trading to $3.79, after it shook hands with UnitedHealthcare who agreed to cover Interpace’s ThyraMIR® test.
The test is used to reduce the rate of unnecessary surgeries in indeterminant cases following thyroid nodule biopsy. Interpace Diagnostics Group Inc. (NASDAQ:IDXG) said the coverage is now in effect and is subject to members’ specific benefit plan design.
In a press release, the company said:
ThyGenX – ThyraMIR represents the only test in the market that combines the rule-in properties of next-generation sequencing of a patient’s DNA and RNA, with rule-out capabilities of a micro-RNA classifier to provide physicians with clinically actionable test results. Based on current performance, over 80% of the Company’s total cases are reflexed to ThyraMIR for additional assessment. The Company first launched ThyraMIR on April 15, 2015 making it available to Endocrinologists and Pathologists throughout the country. Since then, the Company has conducted over 5,000 ThyraMir tests for nearly 400 physicians and hospitals.
The volume reached nearly 24 million trades, which is above its average of 1 million.
The mission of Interpace Diagnostics Group Inc. (NASDAQ:IDXG) is to improve patient care through personalized medicine and molecular diagnostic tests supported by rigorous science. It is focused on developing and commercializing molecular diagnostic tests for better patient diagnosis and management.
What Does The Smart Money Sentiment Say?
At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 39.7% gains over the past 12 months and outperformed the 24.1% gain enjoyed by the S&P 500 ETFs. Our enhanced small-cap hedge fund strategy returned more than 45% over the last 12 months and outperformed SPY by more than 30 percentage points over the last 4.5 years (see details here).
None of the funds we track currently hold shares of Interpace Diagnostics Group Inc. (NASDAQ:IDXG).
The Bottom Line
Traders are flocking Interpace Diagnostics Group Inc. (NASDAQ:IDXG) after UnitedHealthcare agreed to cover Interpace’s ThyraMIR® test. For further reading, here are 11 highest paying healthcare jobs that are in demand in Canada.